0001140361-24-022571.txt : 20240426 0001140361-24-022571.hdr.sgml : 20240426 20240426172055 ACCESSION NUMBER: 0001140361-24-022571 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240426 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240426 DATE AS OF CHANGE: 20240426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STRATA Skin Sciences, Inc. CENTRAL INDEX KEY: 0001051514 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 133986004 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51481 FILM NUMBER: 24885370 BUSINESS ADDRESS: STREET 1: 5 WALNUT GROVE DRIVE STREET 2: SUITE 140 CITY: HORSHAM STATE: PA ZIP: 19044 BUSINESS PHONE: 215-619-3200 MAIL ADDRESS: STREET 1: 5 WALNUT GROVE DRIVE STREET 2: SUITE 140 CITY: HORSHAM STATE: PA ZIP: 19044 FORMER COMPANY: FORMER CONFORMED NAME: MELA SCIENCES, INC. /NY DATE OF NAME CHANGE: 20100504 FORMER COMPANY: FORMER CONFORMED NAME: ELECTRO OPTICAL SCIENCES INC /NY DATE OF NAME CHANGE: 19971216 8-K 1 ef20027726_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 26, 2024

graphic

STRATA SKIN SCIENCES, INC.
(Exact Name of Registrant Specified in Charter)

Delaware
000-51481
13-3986004
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
  
19044
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s telephone number, including area code:   215-619-3200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
SSKN
The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01
Regulation FD Disclosure

On April 26, 2024, Strata Skin Sciences (the “Company”) announced that that the Company will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10 that will become effective at 11:59 p.m. Eastern Time on June 6, 2024. The Company’s common stock will begin trading on Nasdaq on a split-adjusted basis when the market opens on June 7, 2024 under the existing symbol, SSKN, and under a new CUSIP number, 86272A 305. This reverse stock split is primarily intended to bring the Company into compliance with Nasdaq’s minimum bid price requirement for continued listing. Dr. Dolev Rafaeli, the Company’s Vice-Chairman and CEO stated that “On October 26, 2023, shareholders approved a proposal for a reverse split between a ratio of 1-for-5 and 1-for-25. We have until June 6, 2024 for the stock to trade above Nasdaq’s $1.00 per share minimum bid price rule before we would feel compelled to move forward with the reverse split.  Today’s announcement of the exact reverse split ratio simply satisfies the requirement from that shareholder approval that we announce the proposed reverse split ratio by April 26, 2024.”

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01
Financial Statements and Exhibits

(d)
Exhibits

Strata Skin Sciences Press Release dated April 26, 2024
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
STRATA SKIN SCIENCES, INC.
  
       
Date: April 26, 2024
By:
/s/ Christopher Lesovitz
  
   
Christopher Lesovitz
  
   
Chief Financial Officer
  

 
 EX-99.1 2 ef20027726_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

Exhibit 99.1 Strata Skin Sciences Press Release dated April 26, 2024.
 
STRATA Skin Sciences Announces 1-for-10 Reverse Stock Split

HORSHAM, Penn., April 26, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10 that will become effective at 11:59 p.m. Eastern Time on June 6, 2024. The Company’s common stock will begin trading on Nasdaq on a split-adjusted basis when the market opens on June 7, 2024 under the existing symbol, SSKN, and under a new CUSIP number, 86272A 305. This reverse stock split is primarily intended to bring the Company into compliance with Nasdaq’s minimum bid price requirement for continued listing.

“On October 26, 2023, shareholders approved a proposal for a reverse split between a ratio of 1-for-5 and 1-for-25,” commented STRATA’s President and CEO Dr. Dolev Rafaeli.  “We have until June 6, 2024 for the stock to trade above Nasdaq’s $1.00 per share minimum bid price rule before we would feel compelled to move forward with the reverse split.  Today’s announcement of the exact reverse split ratio simply satisfies the requirement from that shareholder approval that we announce the proposed reverse split ratio by April 26, 2024.”
 
Upon effectiveness of the reverse stock split, every ten shares of the Company’s common stock issued and outstanding will be automatically combined into one share of common stock. Outstanding equity-based awards and other equity rights will be proportionately adjusted. No fractional shares will be issued as a result of the reverse stock split. Stockholders who would otherwise hold a fractional share as a result of the reverse stock split will receive an amount of cash equal to the product of (i) the fractional share to which the holder would otherwise be entitled and (ii) the closing price per share on the trading day immediately preceding the effective time of the reverse stock split (as adjusted to give effect to the reverse stock split), without interest.
 
The reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. Stockholders of record will be receiving information from Equiniti (formerly known as American Stock Transfer) , the Company’s transfer agent, regarding their stock ownership following the reverse stock split.

Stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker’s particular processes, and will not be required to take any action in connection with the reverse stock split. Additional information concerning the reverse stock split can be found in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on September 25, 2023.

About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor
This press release includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

Investor Contact:
CORE IR
516-222-2560

 
 EX-101.SCH 3 sskn-20240426.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sskn-20240426_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 sskn-20240426_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00001.jpg begin 644 image00001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# 8$!08%! 8&!08'!P8("A *"@D) M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_ MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P 1" M (<# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#WSQYXGO=% MGT?2]#LHKS7-8F>&U6=RD,81=SR2$<[5'8S MO+8GVGQ&:\G-EJOAE+4N3$LMG,6"YX!(?DXK;\&^* M+'Q7IDEU8I/!+!*UO=6MPFR6VF7[T;CL1D>Q!%;U 'E?A?4O'GBC0[?5]%U[ MPO/87!<1R-IUPA.QRC<%P?O*:])TT7L>EP#5)()+Y8_WSP*5C9NY4$D@5Y]^ MS;_R1C0/]^[_ /2J:O2Y/N-]* /*?!&L>/O%^@C5[34O#]G!)/-$D,EA([ ) M(R\D2#/3TJ_J_B/Q?X,MQJ/BBWTC5-!C=5NKG3EDAGME)QYC1N6#(.^&! Y] M:YCX+^+3I?@2*T_X1_Q!>;+NZ_?6EGYD;?OGZ-GFK_BKQ1<_$%-2\":'H]_8 MWES HU"?4T$'V6V >%[K3;:8,?--]"\BE<<8VD8.:YSXLZ?<7-_P"/K;7[+1IM=\+KJ%Y%)/#'_9TY#)'C<<[\#&X=:ZSPO;^+XKV4 M^)[[1KFU,>(UL;>2-P^1R2S$8QFL'Q%_R7#P=_V#+_\ G%7HAX'- '(?$CQ) M?:'8V-GH$,-SXAU2X%K8PS9V ]7D?'.U5!)_"KO@#Q(/%7A>UU%XOL]X"T%Y M;GK!<(=LB'Z,#CVQ7,>!?^*N\;:IXSE^;3;;=I6C9Z-&I_?3C_?<;0?1*5_^ M*,^*@?[FB>*SM;^[%J"+Q]/,08]V7WH ](HHHH YCQGHFK:A/INH^'=2%EJ6 MGNS+%.&:WN4889)5!S[AAR#6;_;'CXV_E_\ "*:4+K&/-.J_NL^N/+W8KN:J MZE?0Z=:^?9(JDK\N=V#WQ@YQ0!S?PA\-WOA'X>Z7HFJ-"UW;-.7,+;E^>>1Q@X M'9A78,,J1ZBJ5UJMI:W5E!<2A)+PD0Y!PQ SC/0'TSUJS:W$=U%YD)W)N9,X MQRK%3^H- '+?"OP[>>%O!T.EZDT37"3SR$Q-E M'YH[3Q-IC;K2=R0DJ$C?!+CJC ?@<$>_07>KV]M>-:E9I9DC$KK%&7*H20#@ M:C%;3K (YIYRN_RX4W$+G&3V Z]>N#CI0!8@:9K5&FC5)R@+QJV M0&QR ?3/>N5^'7AN\T6'5=1UUXI=?UB[:ZO'B)*(H^6*)2>2J( ![DUT1U*W M$=H[%T%TXCB#1LI+$$X((R.AZTV/5(9;V:VB2=WAD$4C+&=JL55L9^C*?QH MO, RD$9!&"#WKD/AUX=O?"D.J:2S1-HB7;3:6%8EXH7^8Q,.P5B<8[&M^;6; M*&XO8)92LMG"+B52IX0@G(]>AZ?UJ2]U**TDBB*2S3RJ62*)-S$#&3Z B,7V*PL[JWE!;YRTA3;@>GRFK7Q L-7U7PK=Z=X>FBM M[R\Q UP[$>3$QQ(Z\'+!,.IPYS MGBM*B@#/N--^TK8>?<2/):RB;>0 7(!'(' Z]JK0Z*8-8N;Z*6(_:)A,P>(E M@1&J8#;AQA!V[FMFB@##UOPW;ZO'>"6:6*6X0*DL9PT)"EKIUPPR#P>1@BM&B@#'U31FU'2XK6YNB\B3QW'F-&,, MR.' *C''&.OXU*^FR/I1LVE@Z]H 4(S]TJ2 XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
Apr. 26, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 26, 2024
Entity File Number 000-51481
Entity Registrant Name STRATA SKIN SCIENCES, INC.
Entity Central Index Key 0001051514
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 13-3986004
Entity Address, Address Line One 5 Walnut Grove Drive
Entity Address, Address Line Two Suite 140
Entity Address, City or Town Horsham
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19044
City Area Code 215
Local Phone Number 619-3200
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SSKN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://strataskinsciences.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - ef20027726_8k.htm 11 ef20027726_8k.htm sskn-20240426.xsd sskn-20240426_lab.xml sskn-20240426_pre.xml image00001.jpg http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20027726_8k.htm": { "nsprefix": "sskn", "nsuri": "http://strataskinsciences.com/20240426", "dts": { "inline": { "local": [ "ef20027726_8k.htm" ] }, "schema": { "local": [ "sskn-20240426.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "sskn-20240426_lab.xml" ] }, "presentationLink": { "local": [ "sskn-20240426_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://strataskinsciences.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240426to20240426", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20027726_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240426to20240426", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20027726_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001140361-24-022571-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-022571-xbrl.zip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ef20027726_8k_htm.xml IDEA: XBRL DOCUMENT 0001051514 2024-04-26 2024-04-26 false 0001051514 NASDAQ 8-K 2024-04-26 STRATA SKIN SCIENCES, INC. DE 000-51481 13-3986004 5 Walnut Grove Drive Suite 140 Horsham PA 19044 215 619-3200 false false false false Common Stock, $0.001 par value per share SSKN false